Roivant Sciences Ltd. Common Shares
Here’s whether Roivant Sciences Ltd. Common Shares (ROIV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.15% over 10 days); RSI 51 — healthy momentum range; strong 1-year return of +161.9%; 3-month momentum positive (+6.2%). Concerns: declining volume on rally — weak conviction (0.76x 30d avg). Currently 8.4% off its 52-week high. Score: +6/7.
ROIV is in a confirmed uptrend, trading above both its 50-day ($28.91) and 200-day ($23.18) moving averages. An RSI of 50.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +161.9% compares to +22.9% for SPY (beat the market by 139.0%).